SCHEMBL24092000

SCHEMBL24092000

c1ccc2nc(NC3CCC3)ccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.57
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NCF1 P14598 1/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
DDB1 Q16531 1/20 0.51
CRBN Q96SW2 1/20 0.51
PDE10A Q9Y233 4/20 0.47
MAOB P27338 1/20 0.47
CXCR3 P49682 1/20 0.47
MAP4K4 O95819 1/20 0.44
CTSK P43235 1/20 0.44
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
PDE5A O76074 2/20 0.42
ACP1 P24666 2/20 0.42
HCAR3 P49019 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29911218 1.00 MCHR1 (0.57) MCHR1KDM4ELMNASMN1; SMN2NCF1
SCHEMBL16666168 0.96 NPC1 (0.56) MCHR1KDM4ELMNASMN1; SMN2NCF1
SCHEMBL9056686 0.95 NPC1 (0.59) MCHR1KDM4ELMNASMN1; SMN2NCF1
Hydrochloric Acid SCHEMBL8852766 0.93 NPC1 (0.57) MCHR1KDM4ELMNASMN1; SMN2NCF1
SCHEMBL31620776 0.93 NCF1 (0.57) MCHR1KDM4ELMNASMN1; SMN2NCF1
SCHEMBL5943465 0.86 MCHR1 (0.56) MCHR1KDM4ELMNASMN1; SMN2NCF1
SCHEMBL5943499 0.85 NCF1 (0.49) MCHR1KDM4ELMNASMN1; SMN2NCF1
SCHEMBL30824493 0.85 PDE10A (0.59) MCHR1KDM4ELMNASMN1; SMN2NCF1
SCHEMBL7698523 0.85 NPC1 (0.49) MCHR1NCF1NPC1RAB9ADDB1
SCHEMBL6456504 0.85 NCF1 (0.49) MCHR1KDM4ELMNASMN1; SMN2NCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2024-04-09 US disclosed
US-11198699-B2 Compounds targeting PRMT5 ALIGOS THERAPEUTICS, INC. (US) 2021-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11198699-B2 Compounds targeting PRMT5 PRMT5, PRMT1, PRMT6 MCHR1 2833/4885KDM4E 47/4885LMNA 2624/4885
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 MCHR1 3974/4885KDM4E 47/4885LMNA 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.